Evidence map›Paper›PMID 38415469›Full record

ArticleCurrent cancer drug targets2025

TBOPP, a DOCK1 Inhibitor, Potentiates Cisplatin Efficacy in Breast Cancer by Regulating Twist-mediated EMT.

Xin Chen, Zhenbang Zhou, Pengting Tang, Feiya Du, Shuqian Wang, Jia Yao, Shufen Zhang, Jiajing Huang, Xuemei Lu, Wei Chen and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current cancer drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Xin ChenDepartment of Surgery, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310006, China.
Zhenbang ZhouCancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China.
Pengting TangDepartment of Surgery, Ninghai Maternity and Child Health Hospital, Ninghai, Zhejiang, 315600, P.R. China.
Feiya DuDepartment of Orthopaedics, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
Shuqian WangDepartment of General Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
Jia YaoDepartment of General Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
Shufen ZhangCancer Institute of Integrated traditional Chinese and Western Medicine, Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine of Zhejiang Province, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang Province, China.
Jiajing HuangCancer Institute of Integrated traditional Chinese and Western Medicine, Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine of Zhejiang Province, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang Province, China.
Xuemei LuCancer Institute of Integrated traditional Chinese and Western Medicine, Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine of Zhejiang Province, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang Province, China.
Wei ChenCancer Institute of Integrated traditional Chinese and Western Medicine, Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine of Zhejiang Province, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang Province, China.
Xiaofang YuCancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China.
Yu LiuDepartment of General Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.
Hao LiuCancer Institute of Integrated traditional Chinese and Western Medicine, Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine of Zhejiang Province, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang Province, China.ORCID 0000-0002-6040-4651
Zhejiang University · CNTongde Hospital of Zhejiang Province · CNWomen's Hospital, School of Medicine, Zhejiang University · CN

Funding

National Natural Science Foundation of China 82171827Natural Science Foundation of Zhejiang Province LTGY24H160009
6 · The paper itself

Abstract

backgroundDOCK1 has been reported to be involved in tumor progression and re-sistance.1-(2-(30-(trifluoromethyl)-[1,10-biphenyl]-4-yl)-2-oxoethyl)-5-pyrrolidinylsulfonyl2(1H)- pyridone (TBOPP) is a selective DOCK1 inhibitor; however, the role and molecular mechanisms of DOCK1 and its inhibition in breast cancer (BC) resistance remain poorly understood.

objectiveThis study aims toinvestigate the underlying mechanisms of DOCK1 in BC resistance.

objectiveThis study aims toinvestigate the underlying mechanisms of DOCK1 in BC resistance.

methodsDOCK1 or Twist siRNA and Twist plasmid were used to explore the function of DOCK1

resultsIn the present study, we demonstrated that DOCK1 siRNA promoted cisplatin sensitivity in BC cells. Moreover, TBOPP also enhances the therapeutic effect of cisplatin both

conclusionTaken together, these results demonstrate that DOCK1 may function as a potential therapeutic target in BC and that combining cisplatin with TBOPP may provide a promising therapeutic strategy for cisplatin-resistant BC patients.

Indexed as

Breast NeoplasmsCisplatinEpithelial-Mesenchymal TransitionNuclear ProteinsPyridonesTwist-Related Protein 1AnimalsAntineoplastic AgentsCell Line, TumorDrug Resistance, NeoplasmDrug SynergismFemaleHumansMiceMice, Inbred BALB CMice, NudeAntineoplastic AgentsCisplatinDOCK1 protein, humanNuclear ProteinsPyridonesrac GTP-Binding ProteinsTWIST1 protein, humanTwist-Related Protein 1Breast cancercisplatinDOCK1epithelial-mesenchymal transitionTBOPP.TWIST 1

Identifiers

PMID38415469
PMCPMC11826914
OpenAlexW4392353405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.